Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03190278
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
BIOLOGICAL:
UCART123v1.2
Sponsor
Cellectis S.A.